Zobrazeno 1 - 10 of 2 128 pro vyhledávání: '"Chellappa, S"'
3
Akademický článek
Development of a Bead-Based Multiplex Fluorescent Immunoassay to Detect Antibodies against Maedi-Visna Virus in Sheep.
Autor: Borge AJ; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Colitti B; Department of Veterinary Science, University of Turin, Largo P. Braccini 2, 10095 Grugliasco, TO, Italy., Rosati S; Department of Veterinary Science, University of Turin, Largo P. Braccini 2, 10095 Grugliasco, TO, Italy., Nordstoga AB; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Gjerset B; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Udjus K; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Nogarol C; In3diagnostic s.r.l., Largo P. Braccini 2, 10095 Grugliasco, TO, Italy., Chellappa S; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Samdal IA; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway., Lybeck K; Norwegian Veterinary Institute, P.O. Box 64, 1431 Ås, Norway.
Publikováno v: Animals : an open access journal from MDPI [Animals (Basel)] 2024 May 12; Vol. 14 (10). Date of Electronic Publication: 2024 May 12.
Zobrazit plný text záznamu
6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
EXPERIMENTAL INVESTIGATION OF HYBRID COMPOSITE MATERIAL FOR AQUA SILENCERS
Autor: Chellappa, S.
The noise produced from internal combustion engines of automotive vehicles causes a lot of noise pollution to the environment. The harmful gases and noise from the exhaust of IC engines are prevented from free release to the environment by using AQUA
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b4039cf907cde1a856dc93f2e8c28cc6
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
Autor: Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Isaksen K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Chellappa S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Førsund MS; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Spetalen S; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Østenstad B; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Newman AM; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Lorenz S; Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Alizadeh AA; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Publikováno v: Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7216-7230.
Zobrazit plný text záznamu
10
Akademický článek
A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses.
Autor: Kuczkowska K; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway. kkuczkowska@nykode.com., Bjerkan L; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Stubsrud E; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Husbyn HC; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Chellappa S; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway.; Veterinærinstituttet, Elizabeth Stephansens Vei 1, 1433, Ås, Norway., Hauge A; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Skarshaug R; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Torgersen ML; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Heim JB; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Jørgensen MJ; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Wold CW; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Schleimann MH; Department of Clinical Medicine/Infectious Diseases, Aarhus University, Palle Juul-Jensens Boulevard 45, 8200, Aarhus N, Denmark., Tolstrup M; Department of Clinical Medicine/Infectious Diseases, Aarhus University, Palle Juul-Jensens Boulevard 45, 8200, Aarhus N, Denmark., Granum S; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Fredriksen AB; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Pedersen MW; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway., Norheim G; Nykode Therapeutics AS, Oslo Research Park, Gaustadalléen 21, 0349, Oslo, Norway.
Publikováno v: Scientific reports [Sci Rep] 2023 Nov 02; Vol. 13 (1), pp. 18902. Date of Electronic Publication: 2023 Nov 02.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje